Company description

We were incorporated as a Delaware corporation in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo- Acoustic Enhanced Ultrasound, or TAEUS®. Our initial focus for the development and commercialization of TAEUS is a solution for the assessment of liver fat, a key biomarker associated with metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (“MASLD”) and metabolic dysfunction-associated steatohepatitis (“MASH”). Our objective is to develop a scalable biomarker solution for metabolic disease assessment and management through a non-invasive, point- of-care approach. We have periodically evaluated and refined our vision, purpose, and go-to-market strategy with respect to TAEUS in response to evolving market conditions and development priorities. To support adoption across targeted market segments, we are focused on: ● Leveraging artificial intelligence and machine learning models to enhance measurement accuracy accuracy and reproducibility; ● Integrating thermo-acoustic technology with conventional ultrasound to streamline workflows and reduce operator variability; and ● Reducing system size and cost to improve accessibility across care settings. For our go-to-market strategy, we intend to focus on serving these four markets: 1. Pharmaceutical Companies and Clinical Research Organizations (“CROs”); 2. High-end Primary Care Networks (Concierge Medicine); 3. Bariatric and Metabolic Clinics; and 4. Primary and Internal Medicine Practices.

Read the full filing description · filed 31 Mar 2026

At a glance

Sector

Healthcare

Industry

Electromedical & Electrotherapeutic Apparatus